DASH4D diet for glycemic control and glucose variability in type 2 diabetes: a randomized crossover trial.

In this randomized crossover feeding trial, 89 participants with type 2 diabetes were fed four isocaloric diets in a random order: the DASH4D diet (a DASH-style diet tailored for diabetes) or a comparison (typical American) diet, each with higher (3,700 mg day-1 at 2,000 kcal) or lower (1,500 mg day-1 at 2,000 kcal) sodium.

在这项随机交叉喂养试验中，89名2型糖尿病患者按随机顺序接受四种等热量饮食：DASH4D饮食（一种为糖尿病定制的DASH风格饮食）或对照饮食（典型美国饮食），每种饮食的钠含量较高（每天3,700毫克，2,000千卡）或较低（每天1,500毫克，2,000千卡）。

Each feeding period lasted 5 weeks.

每个喂养期持续5周。

The primary outcomes were mean glucose; percentage of time spent with glucose between 70 and 180 mg dl-1 (time in range); and coefficient of variation assessed using 14 days of continuous glucose monitoring during each feeding period.

主要结果包括平均血糖值；血糖在70至180 mg/dl范围内的时间百分比（目标范围内时间）；以及使用连续血糖监测14天评估的变异系数，这些评估均在每个喂养期内进行。

The DASH4D (versus comparison) diet significantly reduced mean glucose (mean difference = -11.1 mg dl-1; P < 0.001), increased time in range (mean difference = +5.2 percentage points; P < 0.001) and had no effect on the coefficient of variation (P = 0.52).

DASH4D（与对照组相比）饮食显著降低了平均血糖（平均差异 = -11.1 mg dl-1；P < 0.001），增加了在目标范围内的平均时间（平均差异 = +5.2个百分点；P < 0.001），并且对变异系数没有影响（P = 0.52）。

In analyses of secondary outcomes, glucose standard deviation and time spent with hyperglycemia (glucose >180 mg dl-1 and >250 mg dl-1) were lower in the DASH4D diet, but time spent with hypoglycemia (glucose <70 mg dl-1 and <54 mg dl-1) was similar across diets.

在次要结果分析中，DASH4D饮食组的血糖标准差和高血糖时间（血糖>180 mg dl-1和>250 mg dl-1）较低，但各饮食组的低血糖时间（血糖<70 mg dl-1和<54 mg dl-1）相似。

There were no serious adverse events related to continuous glucose monitoring or the study diets.

连续血糖监测或研究饮食方案未引发严重不良事件。

These results suggest that the DASH4D diet is a promising nutritional approach to substantially improve glycemic control in adults with type 2 diabetes.

这些结果表明，DASH4D饮食是一种有前景的营养方法，有望显著改善2型糖尿病成人的血糖控制。

ClinicalTrials.gov registration: NCT04286555 .

临床试验注册：NCT04286555 .